<DOC>
	<DOC>NCT01062529</DOC>
	<brief_summary>The aim of this study is to investigate peripheral effects of Somatostatin on glucose metabolism and growth hormone (GH) signalling in healthy men. Eight subjects will be enrolled. The hypothesis is that Somatostatin infusion reverses insulin resistance caused by GH.</brief_summary>
	<brief_title>Peripheral Metabolic Effects of Somatostatin</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>BMI &lt; 27 kg/m2 Written informed consent Healthy Any disease Any use of medications Present or previous malignancy Alcohol dependency Allergy to trial medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>GH signalling</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>somatostatin</keyword>
	<keyword>acromegaly</keyword>
</DOC>